Skip to main content
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
letter
. 1984 Nov 15;131(10):1190.

No crossover of hypersensitivity between zimelidine and fluoxetine.

G Chouinard, B Jones
PMCID: PMC1483702  PMID: 6238668

Full text

PDF

Page 1190

1190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Heel R. C., Morley P. A., Brogden R. N., Carmine A. A., Speight T. M., Avery G. S. Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1982 Sep;24(3):169–206. doi: 10.2165/00003495-198224030-00001. [DOI] [PubMed] [Google Scholar]
  2. Nilsson B. S. Adverse reactions in connection with zimeldine treatment--a review. Acta Psychiatr Scand Suppl. 1983;308:115–119. doi: 10.1111/j.1600-0447.1983.tb11110.x. [DOI] [PubMed] [Google Scholar]
  3. Wong D. T., Horng J. S., Bymaster F. P., Hauser K. L., Molloy B. B. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974 Aug 1;15(3):471–479. doi: 10.1016/0024-3205(74)90345-2. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES